Cesarean Scar Pregnancy and Clinical Outcomes

Sponsor
Peking University Third Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05481606
Collaborator
(none)
500
36

Study Details

Study Description

Brief Summary

This study is a prospective cohort study, led by Prof. Zhao Yangyu, from the Department of Gynecology & Obstetrics, Peking University Third Hospital.

Detailed Description

Cesarean section, myomectomy and other surgeries for uterus are likely to cause scars in different parts of the uterus. During the subsequent pregnancy, the incidence rate of cesarean scar pregnancy, placenta previa, placenta increta and the risk of termination of the first and mid-trimester pregnancy is likely to increase. Cesarean scar pregnancy is regarded as a risk factor of uterine rupture in the third trimester of pregnancy or delivery period, which severely affects the maternal and perinatal health and safety. This study is planning to prospectively include pregnant women aged 20-49 years from Peking University Third Hospital. All women with diagnosis on cesarean scar pregnancy was included prior to 14 wks of gestation. We divided the women into three different groups: type I, type II and type III according to characteristics in gestation sac,uterine scar, bladder, the latter with potentially worse outcomes in term of maternal morbidity and mortality. Data including demographics, medical history, reproductive history, prenatal health care, gestational complications, and pregnancy and birth outcomes will be collected via electronic data capture system.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
500 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Clinical Outcomes of Cesarean Scar Pregnancy With Different Type: a Prospective Cohort Study
Anticipated Study Start Date :
Aug 1, 2022
Anticipated Primary Completion Date :
Aug 1, 2023
Anticipated Study Completion Date :
Aug 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Type I

1) the gestational sac is partially implanted in the uterine scar, partially or mostly located in the uterine cavity, and a few may even reach the uterine cavity at the bottom of the palace; 2) the gestational sac is significantly deformed, and elongated, and its the lower end presented a acute Angle; 3) The myometrium between the gestational sac and the bladder became thinner, with a thickness of >3 mm; 4) Doppler flow image: trophoblast blood flow signal can be seen in the scar (low resistance blood flow)

Type II

1) The gestating sac is partially implanted in the scar of the uterus, partially or mostly located in the uterine cavity, and a few may even reach the uterine cavity at the bottom of the uterus; 2)the gestational sac is significantly deformed, and elongated, and its the lower end presented a acute Angle; 3) The myometrium between the stretch and the bladder becomes thinner (3 mm in thickness); 4) color Doppler flow image: trophoblast blood flow signal (low resistance blood flow) can be seen in the scar.

Type III

1) The gestating sac is completely implanted in the muscle layer of the scar of the uterus and protrudes outward toward the bladder; 2) Uterine cavity and cervical canal emptiness; 3) The myometrium between the gestational sac and the bladder was significantly thinner or absent, with a thickness of 3 mm; 4) color Doppler flow image: trophoblast blood flow signal (low resistance blood flow) can be seen in the scar. Among them, there is a special ultrasonic manifestation of cesarean scar pregnancy in type III, namely mass type, whose sonographic characteristics

Outcome Measures

Primary Outcome Measures

  1. Incidence of blood loss [delivery]

    blood loss

  2. Incidence of postpartum hemorrhage [delivery]

    postpartum hemorrhage

  3. Incidence of maternal transfusion [delivery]

    maternal transfusion

  4. Incidence of spontaneous abortion [delivery]

    spontaneous abortion

  5. Incidence of stillbirth [delivery]

    stillbirth

  6. Incidence of perinatal death [42 days postpartum]

    perinatal death

Secondary Outcome Measures

  1. Maternal death [At 24-28 weeks]

    Deaths during pregnancy or less than 42 days after termination of pregnancy

  2. Maternal death [42 days postpartum]

    Deaths during pregnancy or less than 42 days after termination of pregnancy

  3. The rate of repeated cesarean delivery [At delivery]

    Cesarean rate is defined as the number of cesarean delivery divided by the number of live births.

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 49 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Female aged ≥ 20 years

  • Female with cesarean scar pregnancy

  • Less than 14 gestational weeks

  • Planning to receive prenatal healthcare and delivery service at the study hospital

Exclusion Criteria:
  • Inability to provide informed consent

  • Women with mental disorders

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Peking University Third Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Zhao Yangyu, Chief of obstetrics, Peking University Third Hospital
ClinicalTrials.gov Identifier:
NCT05481606
Other Study ID Numbers:
  • PKUTH22-07-27
First Posted:
Aug 1, 2022
Last Update Posted:
Aug 1, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 1, 2022